Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 400
- Registration Number
- NCT02405156
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2015-09-29
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 423
- Registration Number
- NCT02401425
- Locations
- 🇪🇬
Ain Shams University Maternity Hospital, Cairo, Egypt
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 125
- Registration Number
- NCT02400567
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇫🇷Institut Curie, Paris, France
Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 9
- Registration Number
- NCT02389088
Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Registration Number
- NCT02377479
- Locations
- 🇺🇸
University Hospitals Fertility Center, Beachwood, Ohio, United States
Detect V / CHEVENDO (Chemo vs. Endo)
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 271
- Registration Number
- NCT02344472
- Locations
- 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 137
- Registration Number
- NCT02344550
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02333370
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT02313051
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 140
- Registration Number
- NCT02305693
- Locations
- 🇪🇬
BeniSuef University hospitals, BeniSuef, Egypt
🇪🇬Cairo University Hospitals, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.